Suraksha Clinic and Diagnostics Drives Awareness as Ovarian Cancer Survival Drops to 20% in Late Stages

Kolkata, 20th September, 2025 – Suraksha Diagnostic Limited (“Suraksha Clinic and Diagnostics”), one of the leading diagnostics chains in Eastern India, conducted an insightful online awareness session on ovarian cancer, as part of Ovarian Cancer Awareness Month observed this September. The session was led by Dr. Asima Mukhopadhyay, a globally recognised Gynaecological Oncologist with decades of experience in clinical care, research, and education in the field of women’s cancer. During the online session Dr Asima Mukhopadhyay shared vital insights into how early diagnosis drastically improves survival outcomes, with stage I diagnosis offering up to a 90% cure rate, and stage II a 70% 5-year survival rate. In contrast, survival drops to 20% or less for advanced-stage cases. In this context, the importance of early detection was highlighted. The session also highlighted the silent nature of the disease, the common symptoms often ignored, and the value of early medical intervention.

Ovarian cancer is one of the most common gynaecologic cancers that has the highest mortality rate. It ranks as the third most common cancer among women in India. According to data from the Indian Council of Medical Research (ICMR), the age-adjusted incidence rate stands at approximately 6.8 cases per 100,000 women. Ovarian cancer is also emerging as a global pandemic, with a projected 50 percent rise in global incidence and mortality, with the majority of the burden falling on low and lower-middle income settings. The advanced stage at which most women are diagnosed, leads to poor survival rates and limited treatment options. As a result, international health bodies and international cancer commissions have identified key priority areas that need urgent attention to reduce the burden and improve outcomes worldwide.

These include faster and wider access to early diagnostics such as ultrasound and CA-125 tests, as well as training of general practitioners and community health workers to recognize early symptoms and ensure timely referrals. Another critical area is improving access to genetic testing and counselling as many cancers have genetic predisposition and opportunities for prevention. Additionally, access to high-quality cytoreductive surgery and training is crucial for improving survival in advanced stages. Making targeted therapies such as PARP inhibitors available and affordable is also essential, as these have shown promising results in improving outcomes for specific patient groups. Lastly, ensuring that women have access to clinical trials and survivorship programs is important not only for advancing research but also for supporting long-term health and quality of life after treatment.

During the session Dr Ashima Mukhopadhay highlighted that while people know very commonly about breast cancer, ovarian cancer is not something people are very aware of. However, it is becoming a global pandemic now with the WHO projection of 50% rise in incidence and mortality by 2024. In India around 40,000 women are diagnosed with ovarian cancer every year of which 70% of women die from it. The symptoms of Ovarian cancer being very non-descript gets ignored easily, with most women getting diagnosed at later stages. She informed, compared to the diagnostic rate ovarian cancer has a higher mortality rate. This along with the fact that it is the costliest cancer to treat makes it early diagnosis crucial. Dr Mukhopadhay emphasised that the diagnosis should be done in a lab that has got accreditation, which is being monitored.  Articulating the steps involved in diagnosis, she mentioned ultrasound which gives an idea about the further tests that need to be done. Next are conformity tests like CT Scan that guides one to biopsy which confirms the type of ovarian cancer you have. After that genomics decide how to teat it. Highlighting the importance of molecular diagnostics, he mentioned HRD and BRCA and how they can help assess ones potential risk of developing ovarian cancer and guide cancer treatment, particularly with PARP inhibitors. Lastly Dr Asima Mukhopadahy added to “Be aware of the symptoms, go for diagnosis early. Be aware thsat you may have a problem, don’t be shy about it, report early.”

Speaking on the awareness initiative, Ms. Ritu Mittal, CEO and Managing Director of Suraksha Clinic and Diagnostics, said: “At Suraksha Clinic and Diagnostics, we recognise that diagnostics must be complemented by education and preventive care. With the growing burden of ovarian cancer, particularly in Eastern India, our focus is on enabling early detection through awareness and timely intervention.”

Dr Somnath Chatterjee, Chairman and Joint Managing Director of Suraksha Clinic & Diagnostics, added, “Early diagnosis and timely treatment are critical in improving ovarian cancer outcomes. At Suraksha Clinic and Diagnostics, we are committed to advancing accessible diagnostic services and fostering awareness to support women’s health across the region.”

About Suraksha Clinic and Diagnostics

Established in 1992, Suraksha Clinic and Diagnostics has grown into a prominent diagnostics provider, offering a comprehensive range of over 2,300 tests across pathology, radiology, and medical consultancy services. The company operates a central reference laboratory, eight satellite laboratories, 59 diagnostic centres, and 166 sample collection centres across West Bengal, Bihar, Assam, and Meghalaya. Suraksha's commitment to technological advancement is evident in its adoption of AI-enabled smart labs and digital platforms, streamlining operations and enhancing patient care.  Showcasing its diagnostic excellence, Suraksha Clinic and Diagnostics remains steadfastly dedicated to facilitating early detection of cancer for improved patient outcomes. With its session on Ovarian Cancer, Suraksha Clinic and Diagnostics will be emphasizing the need for public education on early warning signs and encouraging proactive healthcare engagement to improve survival outcome.